Futibatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 4 mg
Reference Brands: Lytgobi (USA)
Category:
Oncology Cancer Care
Futibatinib is available in Tablets
and strengths such as 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Futibatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Futibatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Futibatinib, marketed under the brand name Lytgobi, is an oral anti-cancer medication used for the treatment of adults with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma. It is specifically indicated for patients whose tumors have fibroblast growth factor receptor 2 (FGFR2) gene fusions or other FGFR2 structural alterations and who have previously received systemic therapy.
Futibatinib is a potent tyrosine kinase inhibitor that works by irreversibly blocking FGFR signaling pathways involved in cancer cell growth, survival, and angiogenesis. By inhibiting FGFR activity, Futibatinib helps slow tumor progression and may induce cancer cell death in FGFR-driven tumors. Its irreversible binding mechanism allows sustained inhibition of FGFR, making it effective even in cases where resistance to other FGFR inhibitors may develop.
Administered orally in tablet form, Futibatinib offers a targeted treatment option for patients with limited therapeutic alternatives. In addition to cholangiocarcinoma, Futibatinib is being studied in clinical trials for its potential use in other FGFR-altered malignancies. Lytgobi represents an important advancement in precision oncology, providing targeted therapy based on specific genetic alterations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing